Literature DB >> 33406763

Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression.

Marcello Dallio1, Moris Sangineto2, Mario Romeo1, Rosanna Villani2, Antonino Davide Romano2, Carmelina Loguercio1, Gaetano Serviddio2, Alessandro Federico1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome and has become the major cause of chronic liver disease, especially in western countries. NAFLD encompasses a wide spectrum of hepatic histological alterations, from simple steatosis to steatohepatitis and cirrhosis with a potential development of hepatocellular carcinoma. Non-alcoholic steatohepatitis (NASH) is characterized by lobular inflammation and fibrosis. Several studies reported that insulin resistance, redox unbalance, inflammation, and lipid metabolism dysregulation are involved in NAFLD progression. However, the mechanisms beyond the evolution of simple steatosis to NASH are not clearly understood yet. Recent findings suggest that different oxidized products, such as lipids, cholesterol, aldehydes and other macromolecules could drive the inflammation onset. On the other hand, new evidence indicates innate and adaptive immunity activation as the driving force in establishing liver inflammation and fibrosis. In this review, we discuss how immunity, triggered by oxidative products and promoting in turn oxidative stress in a vicious cycle, fuels NAFLD progression. Furthermore, we explored the emerging importance of immune cell metabolism in determining inflammation, describing the potential application of trained immune discoveries in the NASH pathological context.

Entities:  

Keywords:  hepatocellular carcinoma; non-alcoholic fatty liver disease; oxidative stress; trained immunity

Year:  2021        PMID: 33406763     DOI: 10.3390/ijms22010436

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  15 in total

Review 1.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

2.  Association Between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Risk of Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study.

Authors:  Liping Wang; Jinzhong Dong; Miao Xu; Li Li; Naibin Yang; Guoqing Qian
Journal:  Front Med (Lausanne)       Date:  2022-05-19

3.  Just Drink a Glass of Water? Effects of Bicarbonate-Sulfate-Calcium-Magnesium Water on the Gut-Liver Axis.

Authors:  Antonietta Gerarda Gravina; Mario Romeo; Raffaele Pellegrino; Concetta Tuccillo; Alessandro Federico; Carmelina Loguercio
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

4.  Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Silvia Ferri; Bernardo Stefanini; Lorenzo Mulazzani; Margherita Alvisi; Francesco Tovoli; Simona Leoni; Luca Muratori; Tommaso Lotti; Alessandro Granito; Luigi Bolondi; Fabio Piscaglia
Journal:  Nutrients       Date:  2022-06-16       Impact factor: 6.706

5.  Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1.

Authors:  Raghd Abu Helal; Lucia Russo; Hilda E Ghadieh; Harrison T Muturi; Suman Asalla; Abraham D Lee; Cara Gatto-Weis; Sonia M Najjar
Journal:  Metabolism       Date:  2021-05-28       Impact factor: 13.934

6.  A Novel Nutraceuticals Mixture Improves Liver Steatosis by Preventing Oxidative Stress and Mitochondrial Dysfunction in a NAFLD Model.

Authors:  Moris Sangineto; Vidyasagar Naik Bukke; Francesco Bellanti; Rosanna Tamborra; Archana Moola; Loren Duda; Rosanna Villani; Antonino Davide Romano; Gaetano Serviddio
Journal:  Nutrients       Date:  2021-02-17       Impact factor: 5.717

Review 7.  Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives.

Authors:  Marcello Dallio; Mario Romeo; Antonietta Gerarda Gravina; Mario Masarone; Tiziana Larussa; Ludovico Abenavoli; Marcello Persico; Carmelina Loguercio; Alessandro Federico
Journal:  Nutrients       Date:  2021-05-15       Impact factor: 5.717

8.  Exploring the Protective Effects and Mechanism of Crocetin From Saffron Against NAFLD by Network Pharmacology and Experimental Validation.

Authors:  Zijin Xu; Susu Lin; Junjie Gong; Peishi Feng; Yifeng Cao; Qiaoqiao Li; Yuli Jiang; Ya You; Yingpeng Tong; Ping Wang
Journal:  Front Med (Lausanne)       Date:  2021-06-09

Review 9.  The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis.

Authors:  Jingjing Li; Chuanyong Guo; Jianye Wu
Journal:  Drug Des Devel Ther       Date:  2021-06-18       Impact factor: 4.162

Review 10.  Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.

Authors:  Alvaro Santos-Laso; María Gutiérrez-Larrañaga; Marta Alonso-Peña; Juan M Medina; Paula Iruzubieta; María Teresa Arias-Loste; Marcos López-Hoyos; Javier Crespo
Journal:  Biomedicines       Date:  2021-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.